Cellectar Biosciences Inc at ROTH Conference Transcript
With me now, we have Jim Caruso, the CEO of Cellectar Biosciences. Welcome, Jim.
It's a pleasure to be here, Jonathan. And thank you to all of you for attending this session, very much appreciate it.
Questions & Answers
It's great to have you here. So what prompted you to target a pivotal trial in Waldenstrom's macroglobulinemia -- that's a big mouthful; we'll call it WM -- with your lead drug, iopofosine?
Now that's a great place for us to start. We were in the midst of a Phase 2 trial and a basket study for non-Hodgkin's lymphomas. And we came across a really interesting signal with WM. In fact, of the first six patients that we dosed with iopofosine I 131, we had a 100% response rate.
In fact, the very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
